Zanzalintinib for children with solid tumors that returned or did not respond
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new drug called zanzalintinib in children and teenagers with solid tumors that have come back or not responded to treatment. The goal is to see if the drug is safe and helpful for these patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be under 17 years old.
- You must weigh at least 10 kilograms (about 22 pounds).
- You must be in reasonably good health as measured by a standard scale.
- You must have a solid tumor (including brain tumors) that has returned or not responded to treatment.
- You cannot have lymphoma (a type of blood cancer).
- You cannot have bleeding in the brain or tumors that invade major blood vessels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, zanzalintinib, for people with adenoid cystic carcinoma that has come back or spread and can't be treated with local therapy. The drug may help slow or stop the cancer's growth.
This trial tests a new drug called zanzalintinib for people with advanced liver cancer (HCC) that can't be treated with surgery. You may join if your cancer has gotten worse after at least one prior treatment, or you couldn't tolerate that treatment.
This trial tests a new drug called zanzalintinib for people with advanced or metastatic bone sarcomas that have not responded to standard treatments. It aims to see if the drug can help shrink or slow the growth of these tumors.
This trial tests a new drug called zanzalintinib for people with advanced bladder cancer that has grown after at least one prior treatment. The drug may help shrink tumors or slow their growth.
This trial tests a drug called Zanzalintinib for people with meningioma that has come back or grown despite past treatments. It aims to see if the drug can stop or slow tumor growth.
This trial tests a new targeted therapy pill (XL092, also called zanzalintinib) for people with certain advanced sarcomas that have not responded to other treatments. The goal is to see if the drug shrinks tumors or slows their growth.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.